Oslo, Norway, 18 November 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces that it has entered an agreement with one of the major global pharmaceutical corporations to conduct a feasibility study of circVec-enhanced gene therapy.
The feasibility study involves testing of Circio’s circVec circular RNA expression technology for delivery with AAV vectors in a specific therapeutic area. The project will be performed by Circio and is fully funded by the pharmaceutical company. The agreement does not include any downstream rights or obligations on either party.
“Following the presentation of pre-clinical data showing up to 40-fold advantage for circVec vs. conventional AAVs at major scientific conferences in 2025, Circio has attracted growing interest from a range of prospective gene therapy collaboration partners,” said Dr. Erik Digman Wiklund, CEO of Circio. “Today, Circio has entered its first feasibility study with a major pharmaceutical company. This feasibility study will allow us to broaden the scope of our AAV gene therapy evaluation and serves as an important endorsement of the potential of the circVec platform. We are in parallel exploring opportunities to further expand our gene therapy activities through additional partnerships in other therapeutic areas where circVec has shown promise in pre-clinical studies.”
